Positron ([OTCMKTS:POSC] – Get Free Report) and OPKO Health ([NASDAQ:OPK] – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.\n\nInsider & Institutional Ownership\n---------------------------------\n64.6% of OPKO Health shares are held by institutional investors. 17.2% of Positron shares are held by insiders. Comparatively, 49.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.\n\nRisk and Volatility\n-------------------\nPositron has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.\n\nValuation & Earnings\n--------------------\nThis table compares Positron and OPKO Health”s revenue, earnings per share (EPS) and valuation.\n\n| | | | | | |\n| --- | --- | --- | --- | --- | --- |\n| | **Gross Revenue** | **Price/Sales Ratio** | **Net Income** | **Earnings Per Share** | **Price/Earnings Ratio** |\n| **Positron** | $590,000.00 | 96.56 | \-$2.39 million | ($0.12) | \-14.50 |\n| **OPKO Health** | $713.10 million | 1.38 | \-$53.22 million | ($0.25) | \-5.12 |\n\nPositron has higher earnings, but lower revenue than OPKO Health. Positron is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two
stocks.\n\nProfitability\n-------------\nThis table compares Positron and OPKO Health’s net margins, return on equity and return on assets.\n\n| | | | |\n| --- | --- | --- | --- |\n| | **Net Margins** | **Return on Equity** | **Return on Assets** |\n| **Positron** | N/A | \-278.32% | \-88.36% |\n| **OPKO Health** | \-28.10% | \-13.67% | \-8.70% |\n\nAnalyst Ratings\n---------------\nThis is a summary of recent recommendations for Positron and OPKO Health, as provided by MarketBeat.com.\n\n| | | | | | |\n| --- | --- | --- | --- | --- | --- |\n| | **Sell Ratings** | **Hold Ratings** | **Buy Ratings** | **Strong Buy Ratings** | **Rating Score** |\n| **Positron** | 0 | 0 | 0 | 0 | 0.00 |\n| **OPKO Health** | 1 | 3 | 2 | 1 | 2.43 |\n\nOPKO Health has a consensus price target of $2.28, indicating a potential upside of 78.39%. Given OPKO Health’s stronger consensus rating and higher probable upside, analysts clearly believe OPKO Health is more favorable than Positron.\n\nSummary\n-------\nOPKO Health beats Positron on 11 of the 15 factors compared between the two stocks.\n\nAbout Positron\n--------------\n\n([Get Free Report](https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=OTCMKTS&Symbol=POSC) )\n\nPositron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.\n\nAbout OPKO Health\n-----------------\n\n([Get Free Report](https://www.marketbeat.com/arnreports/ReportTickerOptin.aspx?RegistrationCode=TickerHyperlink&Prefix=NASDAQ&Symbol=OPK) )\n\nOPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company\'s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women\'s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.\n\n**Receive News & Ratings for Positron Daily** - Enter your email address below to receive a concise daily summary of the latest news and analysts\' ratings for Positron and related companies with [MarketBeat.com\'s FREE daily email newsletter](https://www.defenseworld.net/daily-email-updates-basic/?symbol=OTCMKTS:POSC&c=Positron)\n.\n\n \\nYou might be interested in:\n---------------------------\n\n\n\n[Marriott International, Inc. $MAR Shares Sold by Eagle Global Advisors LLC](https://www.defenseworld.net/2026/01/16/marriott-international-inc-mar-shares-sold-by-eagle-global-advisors-llc.html)\n\n\n\n[Fjarde AP Fonden Fourth Swedish National Pension Fund Decreases Holdings in GE Aerospace $GE](https://www.defenseworld.net/2026/01/16/fjarde-ap-fonden-fourth-swedish-national-pension-fund-decreases-holdings-in-ge-aerospace-ge.html)\n\n\n\n[Elwood & Goetz Wealth Advisory Group LLC Acquires 919 Shares of iShares Core S&P 500 ETF $IVV](https://www.defenseworld.net/2026/01/16/elwood-goetz-wealth-advisory-group-llc-acquires-919-shares-of-ishares-core-sp-500-etf-ivv.html)\n\n\n\n[Cullinan Associates Inc. Lowers Stake in Exxon Mobil Corporation $XOM](https://www.defenseworld.net/2026/01/16/cullinan-associates-inc-lowers-stake-in-exxon-mobil-corporation-xom.html)\n\n\n\n[Eastern Bank Cuts Stake in Exxon Mobil Corporation $XOM](https://www.defenseworld.net/2026/01/16/eastern-bank-cuts-stake-in-exxon-mobil-corporation-xom.html)\n\n\n\n[FARMERS & MERCHANTS TRUST Co OF LONG BEACH Has $5.30 Million Holdings in Exxon Mobil Corporation $XOM](https://www.defenseworld.net/2026/01/16/farmers-merchants-trust-co-of-long-beach-has-5-30-million-holdings-in-exxon-mobil-corporation-xom.html)\n\n \\nYou might be interested in:\n---------------------------\n\n[Insider Trading at Positron?](https://www.marketbeat.com/insider-trades/subscribe/?symbol=OTCMKTS:POSC&utm_source=MarketBeatPopup&utm_campaign=MarketBeatPopup&utm_medium=MarketBeatPopup)
